Rik J Scheper

Title: The Innovative Contributions of Rik J Scheper

Introduction

Rik J Scheper is a notable inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of immunotherapy through his innovative research and inventions. With a total of two patents to his name, Scheper's work focuses on the production and application of dendritic cells for therapeutic purposes.

Latest Patents

Scheper's latest patents include the invention of MUTZ-3 dendritic cells. This invention pertains to the production and use of CD124+ and CD116+ cell lines for creating effective dendritic cells (DC) using stimulatory molecules. These cells are utilized in the production of allogenic or semi-allogenic immunotherapeutic agents, which are crucial for treating or preventing immune diseases. Additionally, the invention involves using CD124+ and CD116+ tumor cell lines, preferably also CD34+, as model and test systems for evaluating DC biology and testing substances that impact the immune system.

Another significant patent by Scheper is related to the differentiation of MUTZ-3 cells to produce effective dendritic cells. This patent discloses a method for producing and utilizing CD124+ and CD116+ cell lines in the generation of effective dendritic cells (DC) with the aid of stimulatory molecules.

Career Highlights

Rik J Scheper is currently associated with Glycotope GmbH, where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to revolutionize treatments for various immune-related conditions.

Collaborations

Scheper collaborates with esteemed colleagues such as Steffen Goletz and Alan Masterson, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Rik J Scheper's contributions to the field of immunotherapy through his patents and research are noteworthy. His innovative approaches to dendritic cell production hold promise for advancing therapeutic options in treating immune diseases.